{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:39:00Z","timestamp":1792791540604,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004687","name":"Universidad de Murcia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004687","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Selective oestrogen receptor modulators (SERMs) are a standard treatment for breast cancer and osteoporosis. Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disorder that is a serious public health concern. This study aimed to identify potential pharmacovigilance signals related to dementia and AD for SERMs in menopausal and postmenopausal women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To investigate this possible association, a disproportionality analysis was performed in VigiBase, the World Health Organization\u2019s (WHO) global database of individual case safety reports (ICSRs). Disproportionality was quantified using the reporting odds ratio (ROR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found risk of reporting dementia for tamoxifen [ROR\u2009=\u20091.74 (1.23\u20132.45)] and raloxifene [ROR\u2009=\u20091.63 (1.05\u20132.53)] and AD for raloxifene [ROR\u2009=\u20095.12 (3.26\u20138.05)]. No statistically significant association was detected for fulvestrant and bazedoxifene with dementia or AD. Most of the reports were severe and affected women over the age of 75. The latency of the reactions was predominantly long, suggesting that dementia is a late-onset reaction. The duration of treatment varied from a few months to more than three years, which may indicate that long-term exposure to SERMs is not necessary to develop dementia associated with these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Signals of disproportionate reporting have been observed between the incidence of dementia and AD with SERMs. There are conflicting results from the different studies that have been conducted on the relationship between these drugs and AD. More research is needed to find out what factors determine the risk of cognitive impairment associated with SERMs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04012-y","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:03:05Z","timestamp":1771380185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Selective oestrogen receptor modulators and Alzheimer\u00b4s disease: a real-world pharmacovigilance study"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-8140","authenticated-orcid":false,"given":"Mar\u00eda Teresa","family":"Yuste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0888-4851","authenticated-orcid":false,"given":"Elena","family":"Badillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5532-9888","authenticated-orcid":false,"given":"Juan Sebasti\u00e1n","family":"Galecio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4849-4452","authenticated-orcid":false,"given":"Pedro","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"4012_CR1","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/CON.0000000000001507","volume":"30","author":"GS Day","year":"2024","unstructured":"Day GS (2024) Diagnosing alzheimer disease. Continuum: Lifelong Learn Neurol 30:1584\u20131613","journal-title":"Continuum: Lifelong Learn Neurol"},{"key":"4012_CR2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","volume":"9","author":"W Thies","year":"2013","unstructured":"Thies W, Bleiler L (2013) Alzheimer\u2019s disease facts and figures. Alzheimers Dement 9:208\u2013245","journal-title":"Alzheimers Dement"},{"key":"4012_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/CLEP.S37929","volume":"6","author":"MM Mielke","year":"2014","unstructured":"Mielke MM, Vemuri P, Rocca WA (2014) Clinical epidemiology of Alzheimer\u2019s disease: assessing sex and gender differences. Clin Epidemiol 6:37\u201348","journal-title":"Clin Epidemiol"},{"issue":"4","key":"4012_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4184\/asj.2016.10.4.787","volume":"10","author":"KC An","year":"2016","unstructured":"An KC (2016) Selective estrogen receptor modulators. Asian Spine J 10(4):787\u2013791. https:\/\/doi.org\/10.4184\/asj.2016.10.4.787","journal-title":"Asian Spine J"},{"key":"4012_CR5","first-page":"424","volume":"73","author":"J Ter\u00e1n D\u00e1vila","year":"2005","unstructured":"Ter\u00e1n D\u00e1vila J, Teppa Garr\u00e1n AD (2005) Moduladores selectivos de los receptores estrog\u00e9nicos (SERMs): bioqu\u00edmica, farmacolog\u00eda y aplicaci\u00f3n cl\u00ednica en ginecolog\u00eda. Ginecol Obstet Mex 73:424\u201335","journal-title":"Ginecol Obstet Mex"},{"issue":"10","key":"4012_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2015.124","volume":"12","author":"W Zwart","year":"2015","unstructured":"Zwart W, Terra H, Linn SC, Schagen SB (2015) Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on? Nat Rev Clin Oncol 12(10):597\u2013606","journal-title":"Nat Rev Clin Oncol"},{"key":"4012_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2202-7-74","volume":"7","author":"J Nilsen","year":"2006","unstructured":"Nilsen J, Chen S, Irwin RW, Iwamoto S, Brinton RD (2006) Estrogen protects neuronal cells from amyloid beta\u2013induced apoptosis via regulation of mitochondrial proteins and function. BMC Neurosci 7:74","journal-title":"BMC Neurosci"},{"issue":"4","key":"4012_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nm0498-447","volume":"4","author":"H Xu","year":"1998","unstructured":"Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L et al (1998) Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 4(4):447\u201351","journal-title":"Nat Med"},{"issue":"9","key":"4012_CR9","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.psyneuen.2012.01.007","volume":"37","author":"A Pompili","year":"2012","unstructured":"Pompili A, Arnone B, Gasbarri A (2012) Estrogens and memory in physiological and neuropathological conditions. Psychoneuroendocrinology 37(9):1379\u20131396","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"4012_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1874609811003020113","volume":"3","author":"SC Correia","year":"2010","unstructured":"Correia SC, Santos RX, Cardoso S, Carvalho C, Santos MS, Oliveira CR et al (2010) Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer\u2019s disease? Curr Aging Sci 3(2):113\u201326","journal-title":"Curr Aging Sci"},{"issue":"1","key":"4012_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12035-013-8484-9","volume":"49","author":"JH Lee","year":"2014","unstructured":"Lee JH, Jiang Y, Han DH, Shin SK, Choi WH, Lee MJ (2014) Targeting estrogen receptors for the treatment of alzheimer\u2019s disease. Mol Neurobiol 49(1):39\u201349","journal-title":"Mol Neurobiol"},{"issue":"34","key":"4012_CR12","doi-asserted-by":"publisher","first-page":"8430","DOI":"10.1523\/JNEUROSCI.2752-08.2008","volume":"28","author":"QG Zhang","year":"2008","unstructured":"Zhang QG, Wang R, Khan M, Mahesh V, Brann DW (2008) Role of Dickkopf-1, an antagonist of the Wnt\/\u03b2-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of Tau phosphorylation. J Neurosci 28(34):8430\u20138441","journal-title":"J Neurosci"},{"issue":"11","key":"4012_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1212\/01.wnl.0000276984.19542.e6","volume":"69","author":"WA Rocca","year":"2007","unstructured":"Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andra M (2007) Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69(11):1074\u201383","journal-title":"Neurology"},{"issue":"2","key":"4012_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40261-015-0364-9","volume":"36","author":"I Bakoyiannis","year":"2016","unstructured":"Bakoyiannis I, Tsigka EA, Perrea D, Pergialiotis V (2016) The impact of endocrine therapy on cognitive functions of breast cancer patients: a systematic review. Clin Drug Investig 36(2):109\u2013118. https:\/\/doi.org\/10.1007\/s40261-015-0364-9","journal-title":"Clin Drug Investig"},{"issue":"3","key":"4012_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/jwh.2009.1605","volume":"19","author":"MA Espeland","year":"2010","unstructured":"Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH et al (2010) Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health 19(3):371\u20139. https:\/\/doi.org\/10.1089\/jwh.2009.1605","journal-title":"J Womens Health"},{"key":"4012_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jgo.2020.05.009","volume":"11","author":"PS Blanchette","year":"2020","unstructured":"Blanchette PS, Lam M, Le B, Richard L, Shariff SZ, Pritchard KI et al (2020) The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. J Geriatr Oncol 11:1132\u20137","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"4012_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70075","volume":"13","author":"MT Yuste","year":"2025","unstructured":"Yuste MT, Sainz-Gil M, Escudero E, Mar\u00edn P (2025) Dementia and Alzheimer\u2019s disease associated with aromatase inhibitors: a disproportionality analysis of the WHO pharmacovigilance database (VigiBase). Pharmacol Res Perspect 13(1):e70075. https:\/\/doi.org\/10.1002\/prp2.70075","journal-title":"Pharmacol Res Perspect"},{"issue":"16","key":"4012_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169077","volume":"25","author":"GL Cipriano","year":"2024","unstructured":"Cipriano GL, Mazzon E, Anchesi I (2024) Estrogen receptors: a new frontier in Alzheimer\u2019s disease therapy. Int J Mol Sci 25(16):9077. https:\/\/doi.org\/10.3390\/ijms25169077","journal-title":"Int J Mol Sci"},{"key":"4012_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037","journal-title":"Br J Clin Pharmacol"},{"key":"4012_CR20","unstructured":"Uppsala Monitoring Centre (2025) VigiBase [database on the internet]. Accessed Feb 24"},{"key":"4012_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","volume":"22","author":"A Bate","year":"2008","unstructured":"Bate A, Lindquist M, Edwards IR (2008) The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 22:127\u2013140","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"4012_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Williamson W, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20(2):109\u2013117","journal-title":"Drug Saf"},{"key":"4012_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL (2019) Case\u2013non-case studies: principle, methods, bias and interpretation. Therapies 74:225\u2013232","journal-title":"Therapies"},{"key":"4012_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1278682","volume":"14","author":"R Prevost","year":"2023","unstructured":"Prevost R, Chretien B, Minoc E-M, Dolladille C, Da-Silva A, Nehme A et al (2023) Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4\/6 inhibitors: a pharmacovigilance study using the World Health Organization\u2019s database. Front Pharmacol 14:1278682. https:\/\/doi.org\/10.3389\/fphar.2023.1278682","journal-title":"Front Pharmacol"},{"key":"4012_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.psyneuen.2016.10.020","volume":"75","author":"X Chen","year":"2017","unstructured":"Chen X, Li J, Zhang J, He X, Zhu C, Zhang L et al (2017) Impairment of the executive attention network in premenopausal women with hormone receptor-positive breast cancer treated with tamoxifen. Psychoneuroendocrinology 75:116\u201323. https:\/\/doi.org\/10.1016\/j.psyneuen.2016.10.020","journal-title":"Psychoneuroendocrinology"},{"key":"4012_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.yhbeh.2014.07.005","volume":"66","author":"X Chen","year":"2014","unstructured":"Chen X, Li J, Chen J, Li D, Ye R, Zhang J et al (2014) Decision-making impairments in breast cancer patients treated with tamoxifen. Horm Behav 66:449\u201356. https:\/\/doi.org\/10.1016\/j.yhbeh.2014.07.005","journal-title":"Horm Behav"},{"key":"4012_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11764-008-0070-1","volume":"2","author":"JL Palmer","year":"2008","unstructured":"Palmer JL, Trotter T, Joy AA, Carlson LE (2008) Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2:275\u2013282. https:\/\/doi.org\/10.1007\/s11764-008-0070-1","journal-title":"J Cancer Surviv"},{"issue":"22","key":"4012_CR28","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1212\/WNL.0000000000002171","volume":"85","author":"VW Henderson","year":"2015","unstructured":"Henderson VW, Ala T, Sainani KL, Bernstein AL, Stephenson BS, Rosen AC et al (2015) Raloxifene for women with Alzheimer disease: a randomized controlled pilot trial. Neurology 85(22):1937\u201344. https:\/\/doi.org\/10.1212\/WNL.0000000000002171","journal-title":"Neurology"},{"key":"4012_CR29","doi-asserted-by":"publisher","unstructured":"Kara F, Lohse CM, Castillo AM, Tosakulwong N, Lesnick TG, Jack CR Jr et al (2023) Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration. Cancer Med 12(3):2805\u201317. https:\/\/doi.org\/10.1002\/cam4.5175","DOI":"10.1002\/cam4.5175"},{"issue":"4","key":"4012_CR30","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.21873\/invivo.11615","volume":"33","author":"E Biro","year":"2019","unstructured":"Biro E, Kahan Z, Kalman J, Rusz O, Pakaski M, Irinyi T et al (2019) Cognitive functioning and psychological well-being in breast cancer patients on endocrine therapy. In Vivo 33(4):1381\u201392","journal-title":"In Vivo"},{"issue":"3","key":"4012_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1541","volume":"3","author":"GL Branigan","year":"2020","unstructured":"Branigan GL, Soto M, Neumayer L, Rodgers K, Brinton RD (2020) Association between hormone-modulating breast cancer therapies and incidence of neurodegenerative outcomes for women with breast cancer. JAMA Netw Open 3(3):e201541","journal-title":"JAMA Netw Open"},{"key":"4012_CR32","first-page":"219","volume":"13","author":"MR Thompson","year":"2021","unstructured":"Thompson MR, Niu J, Lei X, Nowakowska M, Wehner MR, Giordano SH et al (2021) Association of endocrine therapy and dementia in women with breast cancer. Breast Cancer (Dove Med Press) 13:219\u2013224","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"4012_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/pon.1860","volume":"21","author":"LM Breckenridge","year":"2012","unstructured":"Breckenridge LM, Bruns GL, Todd BL, Feuerstein M (2012) Cognitive limitations associated with Tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psychooncology 21:43\u201353. https:\/\/doi.org\/10.1002\/pon.1860","journal-title":"Psychooncology"},{"key":"4012_CR34","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.1200\/JCO.2008.21.0716","volume":"27","author":"C Legault","year":"2009","unstructured":"Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB et al (2009) Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the Study of Tamoxifen and Raloxifene. J Clin Oncol 27:5144\u201352. https:\/\/doi.org\/10.1200\/JCO.2008.21.0716","journal-title":"J Clin Oncol"},{"issue":"7","key":"4012_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.22493","volume":"7","author":"C Cai","year":"2024","unstructured":"Cai C, Strickland K, Knudsen S, Tucker SB, Chidrala CS, Modugno F (2024) Alzheimer disease and related dementia following hormone-modulating therapy in patients with breast cancer. JAMA Netw Open 7(7):e2422493. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.22493","journal-title":"JAMA Netw Open"},{"key":"4012_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","volume":"68","author":"D Hirtz","year":"2007","unstructured":"Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R (2007) How common are the \u201ccommon\u201d neurologic disorders? Neurology 68:326\u201337","journal-title":"Neurology"},{"key":"4012_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"GBD 2015 Neurological Disorders Collaborator Group","year":"2017","unstructured":"GBD 2015 Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16:877\u201397https:\/\/doi.org\/10.1016\/S1474-4422(17)30299-5","journal-title":"Lancet Neurol"},{"key":"4012_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir AW (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385\u2013398","journal-title":"Drug Saf"},{"key":"4012_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.therap.2016.09.020","volume":"72","author":"J Bezin","year":"2017","unstructured":"Bezin J, Bosco-Levy P, Pariente A (2017) False-positive results in pharmacoepidemiology and pharmacovigilance. Therapie 72:415\u2013420","journal-title":"Therapie"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04012-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:23:39Z","timestamp":1781634219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04012-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4012"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04012-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have declared that they have no financial or personal relationships with other individuals or organizations that could inappropriately influence the work presented herein.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Vigibase is managed by the Uppsala Monitoring Centre (UMC), the World Health Organization (WHO) Collaborating Centre for International Drug Monitoring. The information comes from a variety of sources, and the probability that the suspected adverse effect is drug-related is not the same in all cases. The discussion and conclusions of this study are authors\u2019 considerations and do not represent the opinion of the UMC or the WHO.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}